332 related articles for article (PubMed ID: 17549381)
21. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G
Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030
[TBL] [Abstract][Full Text] [Related]
22. Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independent mechanisms.
Coudray AM; Louvet C; Kornprobst M; Raymond E; André T; Tournigand C; Faivre S; De Gramont A; Larsen AK; Gespach C
Int J Oncol; 2005 Aug; 27(2):553-61. PubMed ID: 16010439
[TBL] [Abstract][Full Text] [Related]
23. TS mRNA levels can predict pemetrexed and raltitrexed sensitivity in colorectal cancer.
Zhang Q; Shen J; Wang H; Hu J; Yu L; Xie L; Wei J; Liu B; Guan W; Qian X
Cancer Chemother Pharmacol; 2014 Feb; 73(2):325-33. PubMed ID: 24281197
[TBL] [Abstract][Full Text] [Related]
24. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of acquired resistance to thymidylate synthase inhibitors: the role of enzyme stability.
Kitchens ME; Forsthoefel AM; Barbour KW; Spencer HT; Berger FG
Mol Pharmacol; 1999 Nov; 56(5):1063-70. PubMed ID: 10531414
[TBL] [Abstract][Full Text] [Related]
26. Recent advances in the study of rTS proteins. rTS expression during growth and in response to thymidylate synthase inhibitors in human tumor cells.
Dolnick BJ; Lu K; Yin MB; Rustum YM
Adv Enzyme Regul; 1997; 37():95-109. PubMed ID: 9381988
[TBL] [Abstract][Full Text] [Related]
27. Pemetrexed: mRNA expression of the target genes TS, GARFT and DHFR correlates with the in vitro chemosensitivity of human solid tumors.
Eismann U; Oberschmidt O; Ehnert M; Fleeth J; Lüdtke FE; Struck S; Schulz L; Blatter J; Lahn MM; Ma D; Niyikiza C; Paoletti P; Hanauske AR
Int J Clin Pharmacol Ther; 2005 Dec; 43(12):567-9. PubMed ID: 16372519
[No Abstract] [Full Text] [Related]
28. Cross-resistance to antifolates in multidrug resistant cell lines with P-glycoprotein or multidrug resistance protein expression.
van Triest B; Pinedo HM; Telleman F; van der Wilt CL; Jansen G; Peters GJ
Biochem Pharmacol; 1997 Jun; 53(12):1855-66. PubMed ID: 9256160
[TBL] [Abstract][Full Text] [Related]
29. Thymidylate synthase inhibitors.
Danenberg PV; Malli H; Swenson S
Semin Oncol; 1999 Dec; 26(6):621-31. PubMed ID: 10606255
[TBL] [Abstract][Full Text] [Related]
30. Increased thymidylate synthase in L1210 cells possessing acquired resistance to N10-propargyl-5,8-dideazafolic acid (CB3717): development, characterization, and cross-resistance studies.
Jackman AL; Alison DL; Calvert AH; Harrap KR
Cancer Res; 1986 Jun; 46(6):2810-5. PubMed ID: 2938731
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil.
Spears CP; Gustavsson BG; Berne M; Frösing R; Bernstein L; Hayes AA
Cancer Res; 1988 Oct; 48(20):5894-900. PubMed ID: 3167844
[TBL] [Abstract][Full Text] [Related]
32. Increased cytotoxicity and decreased in vivo toxicity of FdUMP[10] relative to 5-FU.
Liu J; Skradis A; Kolar C; Kolath J; Anderson J; Lawson T; Talmadge J; Gmeiner WH
Nucleosides Nucleotides; 1999 Aug; 18(8):1789-802. PubMed ID: 10478484
[TBL] [Abstract][Full Text] [Related]
33. The role of alpha-folate receptor-mediated transport in the antitumor activity of antifolate drugs.
Theti DS; Jackman AL
Clin Cancer Res; 2004 Feb; 10(3):1080-9. PubMed ID: 14871988
[TBL] [Abstract][Full Text] [Related]
34. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR
Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632
[TBL] [Abstract][Full Text] [Related]
35. Structure-based design of lipophilic quinazoline inhibitors of thymidylate synthase.
Jones TR; Varney MD; Webber SE; Lewis KK; Marzoni GP; Palmer CL; Kathardekar V; Welsh KM; Webber S; Matthews DA; Appelt K; Smith WW; Janson CA; Villafranca JE; Bacquet RJ; Howland EF; Booth CL; Herrmann SM; Ward RW; White J; Moomaw EW; Bartlett CA; Morse CA
J Med Chem; 1996 Feb; 39(4):904-17. PubMed ID: 8632414
[TBL] [Abstract][Full Text] [Related]
36. Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates.
Backus HH; Pinedo HM; Wouters D; Padrón JM; Molders N; van Der Wilt CL; van Groeningen CJ; Jansen G; Peters GJ
Int J Cancer; 2000 Sep; 87(6):771-8. PubMed ID: 10956384
[TBL] [Abstract][Full Text] [Related]
37. Drug-resistant variants of Escherichia coli thymidylate synthase: effects of substitutions at Pro-254.
Fantz C; Shaw D; Jennings W; Forsthoefel A; Kitchens M; Phan J; Minor W; Lebioda L; Berger FG; Spencer HT
Mol Pharmacol; 2000 Feb; 57(2):359-66. PubMed ID: 10648646
[TBL] [Abstract][Full Text] [Related]
38. Biochemical effects of folate-based inhibitors of thymidylate synthase in MGH-U1 cells.
Mitrovski B; Pressacco J; Mandelbaum S; Erlichman C
Cancer Chemother Pharmacol; 1994; 35(2):109-14. PubMed ID: 7987985
[TBL] [Abstract][Full Text] [Related]
39. Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.
Chen VJ; Bewley JR; Andis SL; Schultz RM; Iversen PW; Shih C; Mendelsohn LG; Seitz DE; Tonkinson JL
Br J Cancer; 1998; 78 Suppl 3(Suppl 3):27-34. PubMed ID: 9717988
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of FdUMP[10] in treatment of HT-29 human colon cancer xenografts.
Liu C; Willingham M; Liu J; Gmeiner WH
Int J Oncol; 2002 Aug; 21(2):303-8. PubMed ID: 12118325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]